HCV Treatment
Telaprevir (Incivo) for Chronic Hepatitis C Approved in Europe
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 30 September 2011 00:00
- Written by Janssen
The European Commission last week approved the hepatitis C virus (HCV) protease inhibitor telaprevir for treatment of genotype 1 chronic hepatitis C in both previously untreated people and prior non-responders to interferon-based therapy.
Pharmasset Starts Trial of PSI-7977 and PSI-938 Oral Regimens for All HCV Genotypes
- Details
- Category: HCV Treatment
- Published on Friday, 23 September 2011 00:00
- Written by Pharmasset
Pharmasset last week announced the initiation of a new Phase 2b clinical trial that will test the company's investigational nucleotide HCV polymerase inhibitors, PSI-7977 and PSI-938, in various interferon-sparing oral regimens with or without ribavirin.
Telaprevir plus Standard Therapy Can Produce Hepatitis C Cure in Less Time
- Details
- Category: HCV Treatment
- Published on Thursday, 15 September 2011 00:00
- Written by Liz Highleyman
Adding the hepatitis C virus (HCV) protease inhibitor telaprevir (Incivek) to pegylated interferon plus ribavirin increases the chances of sustained response and many patients achieved a cure with a shorter course of therapy, researchers reported in the September 15, 2011, New England Journal of Medicine.
ICAAC 2011: BMS-790052 plus Standard Therapy Cures Most Genotype 1 Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 19 September 2011 00:00
- Written by Liz Highleyman
Up to 83% of treatment-naive people with difficult-to-treat genotype 1 hepatitis C virus (HCV) infection achieved sustained virological response (SVR) with the experimental HCV NS5A inhibitor BMS-790052 plus pegylated interferon and ribavirin, according to data presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this week in Chicago.
Early Data on BMS-790052 HCV NS5A Inhibitor Published
- Details
- Category: HCV Treatment
- Published on Monday, 12 September 2011 00:00
- Written by Liz Highleyman
Bristol-Myers Squibb's experimental HCV NS5A inhibitor, BMS-790052, demonstrated potent antiviral activity, was well-tolerated, and pharmacokinetic parameters support once-daily dosing, according to a small 14-day proof-of-concept study described in the August 11, 2011, advance online edition of Hepatology.
Web Design and Development by